The efficacy of immune checkpoint inhibitors is limited in patients with high-grade serous ovarian cancer (HGSC).
The predictive and prognostic value of tumor-stroma proportion (TSP) was assessed in patients with HGSC treated with platinum-based chemotherapy and pembrolizumab in the NeoPembrOV trial.
